반응식
[CH3:1][N:2]([CH3:39])[CH2:3][C:4]([N:6]1[C:14]2[C:9](=[CH:10][C:11]([O:37][CH3:38])=[C:12]([NH:15][C:16]3[NH:21][C:20]4=[N:22][CH:23]=[CH:24][C:19]4=[C:18]([NH:25][C:26]4[CH:34]=[C:33]([F:35])[CH:32]=[C:31]([F:36])[C:27]=4[C:28]([NH2:30])=[O:29])[N:17]=3)[CH:13]=2)[CH2:8][CH2:7]1)=[O:5].Cl[C:41]1N=C(NC2C=C(F)C=C(F)C=2C(N)=O)C2C=CN(S(C3C=CC(C)=CC=3)(=O)=O)C=2N=1.CN.CN(CC(N1C2C(=CC(OC)=C(N)C=2)CC1)=O)C>O1CCCC1>[CH3:1][N:2]([CH3:39])[CH2:3][C:4]([N:6]1[C:14]2[C:9](=[CH:10][C:11]([O:37][CH3:38])=[C:12]([NH:15][C:16]3[NH:21][C:20]4=[N:22][CH:23]=[CH:24][C:19]4=[C:18]([NH:25][C:26]4[CH:34]=[C:33]([F:35])[CH:32]=[C:31]([F:36])[C:27]=4[C:28]([NH:30][CH3:41])=[O:29])[N:17]=3)[CH:13]=2)[CH2:8][CH2:7]1)=[O:5]참가 물질
반응물 4
생성물 1
시약·촉매·용매 1
실험 절차
In a manner analogous to General Protocol III, 2-[(2-{[1-(N,N-dimethylglycyl)-5-(methyloxy)-2,3-dihydro-1H-indol-6-yl]amino}-1H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-4,6-difluorobenzamide was prepared from 2-({2-chloro-7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}amino)-4,6-difluorobenzamide (0.3 g, 0.63 mmol), 2.0M methyl amine in tetrahydrofuran, and 1-[(dimethylamino)acetyl]-5-(methyloxy)-2,3-dihydro-1H-indol-6-amine (0.19 g, 0.75 mmol) to afford the title compound (0.043 g, 12% over 3 steps) as an off-white solid. ESIMS (M+H)+=551. 1H NMR (400 MHz, DMSO-d6) δ ppm 2.19 (s, 6 H) 2.79 (d, J=4.58 Hz, 3 H) 3.08 (t, J=8.24 Hz, 2 H) 3.10 (s, 2 H) 3.72 (s, 3 H) 4.11 (t, J=8.24 Hz, 2 H) 6.20-6.22 (m, 1 H) 6.78-6.87 (m, 1 H) 6.90-6.96 (m, 2 H) 7.74 (s, 1 H) 8.46 (s, 2 H) 8.51-8.55 (m, 1 H) 10.75 (s,1 H), 11.28 (bs, 1 H).
출처 및 근거
- ORD 기록
- ord-777173f4b4bf4c48a341bb43e008b864
- 출처 데이터셋
- uspto-grants-2011_07
- 특허 번호
- US07981903B2
연결된 노트
불러오는 중…